{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:01:56Z","timestamp":1785132116747,"version":"3.55.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To observe the efficacy and adverse reactions of eltrombopag combined with rhTPO in the treatment of lymphoma patients with chemotherapy - induced thrombocytopenia (CIT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective study was performed on the clinical data of 61 patients using eltrombopag (75\u00a0mg once a day), 99 patients using rhTPO (15,000\u00a0U once daily), and 50 patients using eltrombopag (75\u00a0mg once a day) combined with rhTPO (15,000\u00a0U once daily) in the treatment of lymphoma with CIT at the First Affiliated Hospital of Guangdong Pharmaceutical University from April 2017 to May 2022.66 patients with lymphoma after chemotherapy without any platelet\u2010stimulating therapy were selected as observation controls. Administration of rhTPO and\/or eltrombopag was initiated concurrently when the platelet count dropped below 50 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L. The primary outcome measures encompassed platelet recovery, treatment duration, bleeding events, platelet transfusion requirements, and adverse events. Eltrombopag and rhTPO were discontinued when platelet count was more than 100 \u00d7 10\n                      <jats:sup>9<\/jats:sup>\n                      \/L.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Pre-chemotherapy platelet count did not differ significantly among the three groups (eltrombopag, rhTPO, and combination), as indicated by P &amp;gt; 0.05. At day 5, mean platelet counts were (54.18 \u00b1 20.63)\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L (eltrombopag) (56.01 \u00b1 28.51)\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L (rhTPO) (68.90 \u00b1 24.73)\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L (combination), and (32.70 \u00b1 15.86)\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L (control). The combination therapy achieved significantly higher values than control (P &amp;lt; 0.001), rhTPO (P = 0.025), and eltrombopag (P = 0.042), while both monotherapies also showed significant elevations relative to control (both P &amp;lt; 0.001). At day 10, the combination group (166.30 \u00b1 62.37 \u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L) exhibited a significantly higher platelet count than the control (71.91 \u00b1 42.12, P &amp;lt; 0.001), the rhTPO group (143.31 \u00b1 112.45, P = 0.015), and the eltrombopag group (123.75 \u00b1 47.90, P = 0.036). All three treatment groups demonstrated a significantly lower bleeding incidence versus the control group. The combination group had the lowest proportion of platelet transfusion units per patient (32.0%), whereas the control group had the highest (72.7%), with the eltrombopag and rhTPO groups showing intermediate rates (54.1% and 50.5%, respectively). All three treatment regimens exhibited adverse events that were mild in severity and clinically acceptable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Eltrombopag combined with rhTPO is a effective and safe treatment for lymphoma with CIT, and the effect of the combination is better than that of eltrombopag or rhTPO alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1879712","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:41:28Z","timestamp":1785130888000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of eltrombopag in combination with recombinant human thrombopoietin (rhTPO) for lymphoma patients with chemotherapy-induced thrombocytopenia"],"prefix":"10.3389","volume":"17","author":[{"given":"Qiuhua","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqiu","family":"Qiu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaolun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmin","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zebing","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyi","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Guangdong Pharmaceutical University","place":["Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/10428190600909115","article-title":"The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes","volume":"48","author":"Bhatia","year":"2009","journal-title":"Leukemia and Lymphoma"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1002\/cncr.35292","article-title":"A real\u2010world observation on thrombopoietic agents for patients with cancer treatment\u2013induced thrombocytopenia in China: a multicenter, cross\u2010sectional study","volume":"130","author":"Chen","year":"2024","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40360-023-00707-5","article-title":"Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a meta-analysis","volume":"24","author":"Chen","year":"2023","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","article-title":"Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist","volume":"27","author":"Erickson-Miller","year":"2009","journal-title":"Stem Cells"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1182\/blood-2023-186682","article-title":"Eltrombopag plus rhtpo for corticosteroid-resistant or relapsed ITP: a prospective observed study","volume":"142","author":"Fu","year":"2023","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/bjh.19797","article-title":"Avatrombopag for the treatment of patients with chemotherapy\u2010induced thrombocytopenia: a case series","volume":"206","author":"Galamaga","year":"2024","journal-title":"Br. J. Haematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e61135","DOI":"10.7759\/cureus.61135","article-title":"Aplastic anemia with thrombosis following the administration of immunosuppressant and thrombopoietin receptor agonist (TPO-RA)","volume":"16","author":"Iino","year":"2024","journal-title":"Cureus"},{"key":"B9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7326\/m14-1589","article-title":"Platelet transfusion: a clinical practice guideline from the AABB","volume":"162","author":"Kaufman","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int. J. Hematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1182\/blood-2023-188288","article-title":"Short-Term efficacy of combination therapy with recombinant human Thrombopoietin (rh-TPO) and Thrombopoietin receptor agonists (TPO-Ra) in patients with severe immune thrombocytopenia","volume":"142","author":"Li","year":"2023","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1683857","DOI":"10.3389\/fphar.2024.1683857","article-title":"The efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trials %J","volume":"16","author":"Li","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"6093","DOI":"10.2147\/ijgm.S323699","article-title":"Dual growth factor (rhTPO + G-CSF) and chemotherapy combination regimen for elderly patients with acute myeloid leukemia: a phase II single-arm multicenter study","volume":"14","author":"Liu","year":"2021","journal-title":"Int. J. General Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2157806","DOI":"10.1080\/09537104.2022.2157806","article-title":"Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory\/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study","volume":"34","author":"Liu","year":"2023","journal-title":"Platelets"},{"key":"B15","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/s12885-018-4365-y","article-title":"Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes","volume":"18","author":"Liutkauskiene","year":"2018","journal-title":"BMC Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/bjh.17334","article-title":"Eltrombopag second\u2010line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off\u2010treatment: results of a phase II, multicentre, prospective study","volume":"193","author":"Lucchini","year":"2021","journal-title":"Br. J. Haematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000531146","article-title":"Long-term safety and efficacy of eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukemia and severe thrombocytopenia: results of the ASPIRE extension study","volume":"146","author":"Mittelman","year":"2023","journal-title":"Acta Haematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"101399","DOI":"10.1016\/j.gore.2024.101399","article-title":"Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers","volume":"53","author":"Moufarrij","year":"2024","journal-title":"Gynecol. Oncol. Rep."},{"key":"B19","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors","year":"2022"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American society of hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1200\/jco.22.02699","article-title":"Eltrombopag for low-risk myelodysplastic syndromes with thrombocytopenia: interim results of a phase II, randomized, placebo-controlled clinical trial (EQOL-MDS)","volume":"41","author":"Oliva","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B22","first-page":"45","article-title":"CSCO clinical guidelines for cancer therapy-induced thrombocytopenia %J Chinese","volume":"13","year":"2024","journal-title":"Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3390\/curroncol32080455","article-title":"Understanding chemotherapy-induced thrombocytopenia: implications for gastrointestinal cancer treatment","volume":"32","author":"Peshin","year":"2025","journal-title":"Curr. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"17588359241260985","DOI":"10.1177\/17588359241260985","article-title":"Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study","volume":"16","author":"Qin","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/wsbm.86","article-title":"Hematopoietic stem cell: self\u2010renewal versus differentiation","volume":"2","author":"Seita","year":"2010","journal-title":"WIREs Syst. Biol. Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/14653240801910897","article-title":"CFU-Megakaryocytic progenitors expanded ex vivo from cord blood maintain their in vitro homing potential and express matrix metalloproteinases","volume":"10","author":"Shirvaikar","year":"2008","journal-title":"Cytotherapy"},{"key":"B27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jtha.2023.09.031","article-title":"Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH subcommittee on hemostasis and malignancy","volume":"22","author":"Soff","year":"2024","journal-title":"J. Thrombosis Haemostasis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/ajh.26338","article-title":"Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy\u2010induced thrombocytopenia","volume":"96","author":"Song","year":"2021","journal-title":"Am. J. Hematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1212772","article-title":"A No-Prophylaxis platelet-transfusion strategy for hematologic cancers","volume":"368","author":"Stanworth","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1182\/blood.2024025067","article-title":"Eltrombopag plus diacerein vs eltrombopag in patients with ITP: a multicenter, randomized, open-label phase 2 trial","volume":"144","author":"Sun","year":"2024","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/ajh.27080","article-title":"Avatrombopag for adults with early versus chronic immune thrombocytopenia","volume":"99","author":"Virk","year":"2023","journal-title":"Am. J. Hematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40360-025-00873-8","article-title":"Safety analysis of romiplostim, eltrombopag, and avatrombopag post-market approval: a pharmacovigilance study based on the FDA adverse event reporting system","volume":"26","author":"Wang","year":"2025","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e25891","DOI":"10.1002\/jcla.25891","article-title":"Head-to-head comparison of eltrombopag versus rhTPO for chemotherapy-induced thrombocytopenia in lymphoma patients: a retrospective observational study","volume":"39","author":"Wang","year":"2025","journal-title":"J. Clin. Laboratory Analysis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12885-019-5354-5","article-title":"Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice","volume":"19","author":"Weycker","year":"2019","journal-title":"BMC Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"102231","DOI":"10.1016\/j.rpth.2023.102231","article-title":"Hetrombopag plus recombinant human thrombopoietin for chemotherapy-induced thrombocytopenia in patients with solid tumors","volume":"7","author":"Xia","year":"2023","journal-title":"Res. Pract. Thrombosis Haemostasis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1111\/jcmm.13809","article-title":"Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist","volume":"22","author":"Xie","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/0008-5472.Can-06-4303","article-title":"Chemotherapy-Induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor","volume":"67","author":"Zeuner","year":"2007","journal-title":"Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.21037\/apm-22-880","article-title":"Cost-effectiveness analysis of rhTPO and rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia in hematological tumors based on real-world data","volume":"11","author":"Zhang","year":"2022","journal-title":"Ann. Palliat. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"14084","DOI":"10.1002\/cam4.6062","article-title":"Incidence, consequences, and predictors of serious chemotherapy\u2010induced thrombocytopenia in nasopharyngeal carcinoma","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/ejh.14418","article-title":"Comparison of hetrombopag and eltrombopag added to first\u2010line immunosuppressive therapy in severe aplastic anemia","volume":"115","author":"Zhang","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10557-016-6696-8","article-title":"Hetrombopag, a Thrombopoietin receptor agonist, protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells","volume":"30","author":"Zhou","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"701539","DOI":"10.3389\/fonc.2021.701539","article-title":"A real-world observation of eltrombopag and recombinant human Thrombopoietin (rhTPO) in lymphoma patients with chemotherapy induced Thrombocytopenia","volume":"11","author":"Zhu","year":"2021","journal-title":"Front. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1879712\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:41:29Z","timestamp":1785130889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1879712\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":41,"alternative-id":["10.3389\/fphar.2026.1879712"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1879712","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1879712"}}